XARELTO (rivaroxaban) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement
Critical priority
The issue
Product safety
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.